Literature DB >> 21742731

IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production.

Maciej Lech1, Marc Weidenbusch, Onkar P Kulkarni, Mi Ryu, Murthy Narayana Darisipudi, Heni Eka Susanti, Hans-Willi Mittruecker, Tak W Mak, Hans-Joachim Anders.   

Abstract

The IFN-regulatory factors IRF1, IRF3, IRF5, and IRF7 modulate processes involved in the pathogenesis of systemic lupus and lupus nephritis, but the contribution of IRF4, which has multiple roles in innate and adaptive immunity, is unknown. To determine a putative pathogenic role of IRF4 in lupus, we crossed Irf4-deficient mice with autoimmune C57BL/6-(Fas)lpr mice. IRF4 deficiency associated with increased activation of antigen-presenting cells in C57BL/6-(Fas)lpr mice, resulting in a massive increase in plasma levels of TNF and IL-12p40, suggesting that IRF4 suppresses cytokine release in these mice. Nevertheless, IRF4 deficiency completely protected these mice from glomerulonephritis and lung disease. The mice were hypogammaglobulinemic and lacked antinuclear and anti-dsDNA autoantibodies, revealing the requirement of IRF4 for the maturation of plasma cells. As a consequence, Irf4-deficient C57BL/6-(Fas)lpr mice neither developed immune complex disease nor glomerular activation of complement. In addition, lack of IRF4 impaired the maturation of Th17 effector T cells and reduced plasma levels of IL-17 and IL-21, which are cytokines known to contribute to autoimmune tissue injury. In summary, IRF4 deficiency enhances systemic inflammation and the activation of antigen-presenting cells but also prevents the maturation of plasma cells and effector T cells. Because these adaptive immune effectors are essential for the evolution of lupus nephritis, we conclude that IRF4 promotes the development of lupus nephritis despite suppressing antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742731      PMCID: PMC3148699          DOI: 10.1681/ASN.2010121260

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  41 in total

1.  Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.

Authors:  David A Savitsky; Hideyuki Yanai; Tomohiko Tamura; Tadatsugu Taniguchi; Kenya Honda
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 2.  Systemic lupus erythematosus.

Authors:  B L Kotzin
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

3.  Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.

Authors:  D Balomenos; R Rumold; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

4.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

5.  Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice.

Authors:  Vasileios C Kyttaris; Zheng Zhang; Vijay K Kuchroo; Mohamed Oukka; George C Tsokos
Journal:  J Immunol       Date:  2010-03-22       Impact factor: 5.422

6.  4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.

Authors:  Onkar P Kulkarni; Sufyan G Sayyed; Claudia Kantner; Mi Ryu; Max Schnurr; Miklós Sárdy; Johann Leban; Ruediger Jankowsky; Aldo Ammendola; Robert Doblhofer; Hans-Joachim Anders
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

7.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 8.  Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation.

Authors:  H Kanta; C Mohan
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

9.  Pseudoviral immunity - a novel concept for lupus.

Authors:  Hans-Joachim Anders
Journal:  Trends Mol Med       Date:  2009-11-04       Impact factor: 11.951

Review 10.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

Authors:  P L Cohen; R A Eisenberg
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

View more
  24 in total

1.  Haploinsufficiency of interferon regulatory factor 4 strongly protects against autoimmune diabetes in NOD mice.

Authors:  Satoru Akazawa; Masakazu Kobayashi; Genpei Kuriya; Ichiro Horie; Liping Yu; Hironori Yamasaki; Minoru Okita; Yuji Nagayama; Toshifumi Matsuyama; Masoud Akbari; Katsuyuki Yui; Atsushi Kawakami; Norio Abiru
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

Review 2.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 4.  Metabolic Factors that Contribute to Lupus Pathogenesis.

Authors:  Wei Li; Ramya Sivakumar; Anton A Titov; Seung-Chul Choi; Laurence Morel
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 5.  A novel pathogenetic concept-antiviral immunity in lupus nephritis.

Authors:  Adriana Migliorini; Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2012-01-17       Impact factor: 28.314

6.  Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy.

Authors:  Ming Li; Ling Wang; Dian-Chun Shi; Jia-Nee Foo; Zhong Zhong; Chiea-Chuen Khor; Chiara Lanzani; Lorena Citterio; Erika Salvi; Pei-Ran Yin; Jin-Xin Bei; Li Wang; Yun-Hua Liao; Jian Chen; Qin-Kai Chen; Gang Xu; Geng-Ru Jiang; Jian-Xin Wan; Meng-Hua Chen; Nan Chen; Hong Zhang; Yi-Xin Zeng; Zhi-Hong Liu; Jian-Jun Liu; Xue-Qing Yu
Journal:  J Am Soc Nephrol       Date:  2020-09-10       Impact factor: 10.121

Review 7.  Interferon regulatory factor signaling in autoimmune disease.

Authors:  Bharati Matta; Su Song; Dan Li; Betsy J Barnes
Journal:  Cytokine       Date:  2017-03-07       Impact factor: 3.861

Review 8.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

9.  Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling.

Authors:  Sokratis A Apostolidis; Thomas Rauen; Christian M Hedrich; George C Tsokos; José C Crispín
Journal:  J Biol Chem       Date:  2013-08-05       Impact factor: 5.157

Review 10.  Pattern recognition receptors and the inflammasome in kidney disease.

Authors:  Jaklien C Leemans; Lotte Kors; Hans-Joachim Anders; Sandrine Florquin
Journal:  Nat Rev Nephrol       Date:  2014-06-03       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.